CLINICAL VARIABLES COULD SURROGATE BLOOD LACTATE LEVELS AS AN EXERCISE INTENSITY MARKER ONLY DURING LOW INTENSITY EXERCISE IN PATIENTS WITH CORONARY ARTERY DISEASE.

2014 ◽  
Vol 25 (4) ◽  
pp. 117
Author(s):  
Alvaro N. Gurovich ◽  
Chase Hayes ◽  
Brittany Heiser ◽  
Stephanie Tobin ◽  
Emily Marshall ◽  
...  
1994 ◽  
Vol 43 (3) ◽  
pp. 211-218
Author(s):  
MASAHIKO AIHARA ◽  
KAZUO TSUYUKI ◽  
MAKOTO AKAIKE ◽  
KENJI NINOMIYA ◽  
KWANGCHOL CHANG ◽  
...  

Author(s):  
Ian Ford ◽  
Michele Robertson ◽  
Nicola Greenlaw ◽  
Christophe Bauters ◽  
Gilles Lemesle ◽  
...  

Abstract Aims Risk estimation is important to motivate patients to adhere to treatment and to identify those in whom additional treatments may be warranted and expensive treatments might be most cost effective. Our aim was to develop a simple risk model based on readily available risk factors for patients with stable coronary artery disease (CAD). Methods and results Models were developed in the CLARIFY registry of patients with stable CAD, first incorporating only simple clinical variables and then with the inclusion of assessments of left ventricular function, estimated glomerular filtration rate, and haemoglobin levels. The outcome of cardiovascular death over ∼5 years was analysed using a Cox proportional hazards model. Calibration of the models was assessed in an external study, the CORONOR registry of patients with stable coronary disease. We provide formulae for calculation of the risk score and simple integer points-based versions of the scores with associated look-up risk tables. Only the models based on simple clinical variables provided both good c-statistics (0.74 in CLARIFY and 0.80 or over in CORONOR), with no lack of calibration in the external dataset. Conclusion Our preferred model based on 10 readily available variables [age, diabetes, smoking, heart failure (HF) symptom status and histories of atrial fibrillation or flutter, myocardial infarction, peripheral arterial disease, stroke, percutaneous coronary intervention, and hospitalization for HF] had good discriminatory power and fitted well in an external dataset. Study registration The CLARIFY registry is registered in the ISRCTN registry of clinical trials (ISRCTN43070564).


Cardiology ◽  
2020 ◽  
Vol 145 (2) ◽  
pp. 63-70
Author(s):  
Yaanik B. Desai ◽  
Rakesh K. Mishra ◽  
Qizhi Fang ◽  
Mary A. Whooley ◽  
Nelson B. Schiller

Background: Serial increases in high-sensitivity cardiac troponin (hs-cTnT) have been associated with death in community-dwelling adults, but the association remains uninvestigated in those with coronary artery disease (CAD). Methods: We measured hs-cTnT at baseline and after 5 years in 635 ambulatory Heart and Soul Study patients with CAD. We also performed echocardiography at rest and after treadmill exercise at baseline and after 5 years. Participants were subsequently followed for the outcome of death. We used a multivariable-adjusted Cox proportional hazards model to evaluate the association between 5-year change in hs-cTnT and subsequent all-cause mortality. Results: Of the 635 subjects, there were 386 participants (61%) who had an increase in hs-cTnT levels between baseline and year 5 measurements (median increase 5.6 pg/mL, IQR 3.2–9.9 pg/mL). There were 182 deaths after a mean 4.2-year follow-up after the year 5 visit. After adjusting for clinical variables, a >50% increase in hs-cTnT between baseline and year 5 was associated with a nearly 2-fold increased risk of death from any cause (hazard ratio 1.7, 95% confidence interval 1.1–2.7). When addition of year 5 hs-cTnT was compared to a model including clinical variables and baseline hs-cTnT, there was a modest but statistically significant increase in C-statistic from 0.82 to 0.83 (p = 0.04). Conclusion: In ambulatory patients with CAD, serial increases in hs-cTnT over time are associated with an increased risk of death.


2020 ◽  
Vol 24 (5) ◽  
pp. 449-457
Author(s):  
Mariana de Oliveira Gois ◽  
Rodrigo Polaquini Simões ◽  
Alberto Porta ◽  
Vandeni Clarice Kunz ◽  
Carlos Marcelo Pastre ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document